目的 探討生脈注射液聯(lián)合重組人腦利鈉肽治療急性心力衰竭的臨床效果。方法 選取2014年1月—2017年10月在中國(guó)人民解放軍第二五四醫(yī)院收治的112例急性心力衰竭患者，隨機(jī)分為對(duì)照組和治療組，每組各56例。對(duì)照組靜脈滴注注射用重組人腦利鈉肽，首次靜脈沖擊1.5 μg/kg，隨后按照0.01 μg/（kg·min）靜脈泵入。治療組在對(duì)照組治療基礎(chǔ)上靜脈滴注生脈注射液，50 mL生脈注射液加入到5%葡萄糖注射液100 mL，1次/d。兩組均連續(xù)治療3 d。觀察兩組的臨床療效，比較兩組治療前后左心室射血分?jǐn)?shù)（LVEF）、左室舒張末內(nèi)徑（LVEDD）、尿素氮（BUN）、肌酐（Cr）、血清腦鈉肽（BNP）的變化情況。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為78.57%、94.64%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P < 0.05）。治療后，兩組患者LVEF顯著升高，但LVEDD、BUN、Cr、BNP顯著降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P < 0.05）；治療后，治療組LVEF高于對(duì)照組，LVEDD、BUN、Cr、BNP低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。結(jié)論 生脈注射液聯(lián)合重組人腦利鈉肽治療急性心力衰竭具有顯著的臨床治療效果，可明顯改善患者心功能，保護(hù)腎功能，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical effect of Shengmai Injection combined with recombinant human brain natriuretic peptide in treatment of acute heart failure. Methods Patients (112 cases) with acute heart failure in No. 254 Hospital of the People's Liberation Army from January 2014 to October 2017 were randomly divided into control (56 cases) and treatment (56 cases) groups. Patients in the control group were iv administered with Recombinant Human Brain Natriuretic Peptide for injection, and the first dosage of intravenous pulse was 1.5 μg/kg, followed by 0.01 μg/(kg·min). Patients in the treatment group were iv administered with Shengmai Injection on the basis of the control group, 50 mL Shengmai Injection added to 5% glucose injection 100 mL, once daily. Patients in two groups were treated for 3 d. After treatment, the clinical efficacy was evaluated, and the changes of LVEF, LVEDD, BUN, Cr, and BNP in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 78.57% and 94.64%, respectively, and there was difference between two groups (P < 0.05). After treatment, LVEF in two groups was elevated, but LVEDD, BUN, Cr, and BNP in two groups reduced significantly, and the difference was statistically significant in the same group (P < 0.05). After treatment, LVEF in the treatment group was higher than that in the control group, but LVEDD, BUN, Cr, and BNP were lower than those in the control group, and there was difference between two groups (P < 0.05). Conclusion Shengmai Injection combined with recombinant human brain natriuretic peptide has remarkable clinical effect in treatment of acute heart failure, and can obviously improve the heart function and protect the renal function, which has a certain clinical application value.